Marco Vignetti | Ricerc@Sapienza

Pubblicazioni

Titolo	Pubblicato in	Anno
Update of the GIMEMA MDS0306 study: Deferasirox for lower risk transfusion-dependent patients with myelodysplastic syndromes	EUROPEAN JOURNAL OF HAEMATOLOGY	2019
TP53 CLONAL AND SUBCLONAL ARCHITECTURE IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS UNDER IBRUTINIB TREATMENT.	HemaSphere	2019
IBRUTINIB TREATMENT DOESN’T INDUCE TP53 CLONAL EVOLUTION IN CHRONIC LYMPHOCYTIC LEUKEMIA.	Haematologica 2019; 104(s2):1	2019
Pretreatment symptom prevalence in patients with myelodysplastic syndromes (MDS) across all disease risk categories: Analysis of 914 patients	JOURNAL OF CLINICAL ONCOLOGY	2019
Fatigue in long-term survivors of acute promyelocytic leukemia (APL) and its association with other symptoms and functional limitations	JOURNAL OF CLINICAL ONCOLOGY	2019
Italian survey on clinical practice in myeloproliferative neoplasms. A GIMEMA Myeloproliferative Neoplasms Working Party initiative	AMERICAN JOURNAL OF HEMATOLOGY	2019
Lymphomatoid granulomatosis and large granular lymphocyte leukemia, a rare association of two lymphoproliferative disorders	LEUKEMIA & LYMPHOMA	2018
Rapid identification of BCR/ABL1-like acute lymphoblastic leukaemia patients using a predictive statistical model based on quantitative real time-polymerase chain reaction: clinical, prognostic and therapeutic implications.	BRITISH JOURNAL OF HAEMATOLOGY	2018
Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study	HAEMATOLOGICA	2018
Prognostic implications of additional genomic lesions in adult Ph+ acute lymphoblastic leukemia	HAEMATOLOGICA	2018
IL7R overexpression in adult acute lymphoblastic leukemia is associated to JAK/STAT pathway mutations and identifies patients who could benefit from targeted therapies	LEUKEMIA & LYMPHOMA	2018
Patient-reported outcomes enhance the survival prediction of traditional disease risk classifications: An international study in patients with myelodysplastic syndromes	CANCER	2018
MTHFR, TS and XRCC1 genetic variants may affect survival in patients with myelodysplastic syndromes treated with supportive care or azacitidine	PHARMACOGENOMICS JOURNAL	2018
Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinib	CANCER	2018
Patient-Reported Outcomes Enhance the Survival Prediction of Traditional Disease Risk Classifications: An International Study in Patients With Myelodysplastic Syndromes	CANCER	2018
Pretreatment Health-Related Quality of Life Profile According to the EORTC QLQ-C30 in Patients with Myelodysplastic Syndromes (MDS): Analysis on 443 Lower-Risk MDS Patients	BLOOD	2018
Clinical and Prognostic Features of Essential Thrombocythemia: Comparison of Who 2001 Versus Who 2008/2016 Criteria in a Large Single Center Cohort	BLOOD	2018
Fludarabine, cyclophosphamide and lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia. A multicenter phase I–II GIMEMA trial	LEUKEMIA & LYMPHOMA	2017
Physicians' attitude towards selection of second line therapy with nilotinib and dasatinib in chronic myeloid leukemia patients	HEALTH AND QUALITY OF LIFE OUTCOMES	2017
Low-dose clofarabine in combination with a standard remission induction in patients aged 18-60 years with previously untreated intermediate and bad-risk acute myeloid leukemia or high-risk myelodysplastic syndrome: Combined phase I/II results of the EORTC/GIMEMA AML-14A trial	HAEMATOLOGICA	2017